Which has higher valuation and earnings, IMUX or ELUT?

Elutia has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$5.58 N/A Elutia $12.29M 3.45 $53.38M $0.86 1.15

Is IMUX or ELUT more profitable?

Elutia has a net margin of 312.09% compared to Immunic's net margin of 0.00%. Elutia's return on equity of 0.00% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -220.75% -132.04% Elutia 312.09% N/A -53.97%

Which has preferable earnings & valuation, ADAG or ELUT?

Elutia has higher revenue and earnings than Adagene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adagene $7.67M 20.14 -$17.61M N/A N/A Elutia $12.29M 3.45 $53.38M $0.86 1.15

Is ADAG or ELUT more profitable?

Elutia has a net margin of 312.09% compared to Adagene's net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Adagene N/A N/A N/A Elutia 312.09% N/A -53.97%

Do analysts rate JMAC or ELUT?

Elutia has a consensus price target of $6.00, suggesting a potential upside of 505.94%. Given Elutia's stronger consensus rating and higher possible upside, analysts plainly believe Elutia is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Elutia 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger earnings and valuation, JMAC or ELUT?

Elutia has higher revenue and earnings than Maxpro Capital Acquisition. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maxpro Capital Acquisition N/A N/A N/A N/A N/A Elutia $12.29M 3.45 $53.38M $0.86 1.15

Is JMAC or ELUT more profitable?

Elutia has a net margin of 312.09% compared to Maxpro Capital Acquisition's net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Maxpro Capital Acquisition N/A N/A N/A Elutia 312.09% N/A -53.97%

Elutia (ELUT) Competitors

$0.99 -0.01 (-0.85%)

Closing price 06/8/2026 04:00 PM Eastern

Extended Trading

$1.00 +0.01 (+0.99%)

As of 06/8/2026 04:10 PM Eastern

Compare

ELUT vs. IMUX, ADAG, JMAC, UNCY, and ARTV

Should you buy Elutia stock or one of its competitors? MarketBeat compares Elutia with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Elutia include Immunic (IMUX), Adagene (ADAG), Maxpro Capital Acquisition (JMAC), Unicycive Therapeutics (UNCY), and Artiva Biotherapeutics (ARTV). These companies are all part of the "pharmaceutical products" industry.

How does Elutia compare to Immunic?

Immunic (NASDAQ:IMUX) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Elutia has higher revenue and earnings than Immunic. Immunic is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$5.58	N/A
Elutia	$12.29M	3.45	$53.38M	$0.86	1.15

51.8% of Immunic shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 5.5% of Immunic shares are held by insiders. Comparatively, 27.6% of Elutia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Immunic had 1 more articles in the media than Elutia. MarketBeat recorded 1 mentions for Immunic and 0 mentions for Elutia. Immunic's average media sentiment score of 0.00 equaled Elutia'saverage media sentiment score.

Company	Overall Sentiment
Immunic	Neutral
Elutia	Neutral

Immunic presently has a consensus price target of $47.57, suggesting a potential upside of 294.46%. Elutia has a consensus price target of $6.00, suggesting a potential upside of 505.94%. Given Elutia's higher probable upside, analysts clearly believe Elutia is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.00
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Immunic has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market. Comparatively, Elutia has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Elutia has a net margin of 312.09% compared to Immunic's net margin of 0.00%. Elutia's return on equity of 0.00% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-220.75%	-132.04%
Elutia	312.09%	N/A	-53.97%

Summary

Elutia beats Immunic on 10 of the 15 factors compared between the two stocks.

How does Elutia compare to Adagene?

Adagene (NASDAQ:ADAG) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability and risk.

Elutia has higher revenue and earnings than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	20.14	-$17.61M	N/A	N/A
Elutia	$12.29M	3.45	$53.38M	$0.86	1.15

Elutia has a net margin of 312.09% compared to Adagene's net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Elutia	312.09%	N/A	-53.97%

Adagene presently has a consensus target price of $8.00, indicating a potential upside of 145.40%. Elutia has a consensus target price of $6.00, indicating a potential upside of 505.94%. Given Elutia's higher probable upside, analysts clearly believe Elutia is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Adagene has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market. Comparatively, Elutia has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

In the previous week, Adagene had 1 more articles in the media than Elutia. MarketBeat recorded 1 mentions for Adagene and 0 mentions for Elutia. Adagene's average media sentiment score of 0.00 equaled Elutia'saverage media sentiment score.

Company	Overall Sentiment
Adagene	Neutral
Elutia	Neutral

9.5% of Adagene shares are held by institutional investors. Comparatively, 74.0% of Elutia shares are held by institutional investors. 21.2% of Adagene shares are held by company insiders. Comparatively, 27.6% of Elutia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Elutia beats Adagene on 7 of the 13 factors compared between the two stocks.

How does Elutia compare to Maxpro Capital Acquisition?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Elutia (NASDAQ:ELUT) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

In the previous week, Maxpro Capital Acquisition's average media sentiment score of 0.00 equaled Elutia'saverage media sentiment score.

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
Elutia	Neutral

73.2% of Maxpro Capital Acquisition shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 19.3% of Maxpro Capital Acquisition shares are owned by insiders. Comparatively, 27.6% of Elutia shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Elutia has higher revenue and earnings than Maxpro Capital Acquisition.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Elutia	$12.29M	3.45	$53.38M	$0.86	1.15

Maxpro Capital Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, Elutia has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Elutia has a consensus price target of $6.00, suggesting a potential upside of 505.94%. Given Elutia's stronger consensus rating and higher possible upside, analysts plainly believe Elutia is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Elutia has a net margin of 312.09% compared to Maxpro Capital Acquisition's net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
Elutia	312.09%	N/A	-53.97%

Summary

Elutia beats Maxpro Capital Acquisition on 8 of the 9 factors compared between the two stocks.

How does Elutia compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Elutia (NASDAQ:ELUT) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, dividends, media sentiment, valuation, profitability, institutional ownership, risk and analyst recommendations.

Elutia has a net margin of 312.09% compared to Unicycive Therapeutics' net margin of 0.00%. Elutia's return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
Elutia	312.09%	N/A	-53.97%

Unicycive Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market. Comparatively, Elutia has a beta of 0.8, indicating that its stock price is 20% less volatile than the broader market.

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 74.0% of Elutia shares are owned by institutional investors. 10.7% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 27.6% of Elutia shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Elutia has higher revenue and earnings than Unicycive Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	261.50	-$26.56M	-$2.21	N/A
Elutia	$12.29M	3.45	$53.38M	$0.86	1.15

In the previous week, Unicycive Therapeutics had 2 more articles in the media than Elutia. MarketBeat recorded 2 mentions for Unicycive Therapeutics and 0 mentions for Elutia. Unicycive Therapeutics' average media sentiment score of 0.46 beat Elutia's score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Unicycive Therapeutics	Neutral
Elutia	Neutral

Unicycive Therapeutics presently has a consensus price target of $24.75, suggesting a potential upside of 271.62%. Elutia has a consensus price target of $6.00, suggesting a potential upside of 505.94%. Given Elutia's higher probable upside, analysts clearly believe Elutia is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Elutia beats Unicycive Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Elutia compare to Artiva Biotherapeutics?

Elutia (NASDAQ:ELUT) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

74.0% of Elutia shares are owned by institutional investors. 27.6% of Elutia shares are owned by insiders. Comparatively, 21.4% of Artiva Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Artiva Biotherapeutics had 3 more articles in the media than Elutia. MarketBeat recorded 3 mentions for Artiva Biotherapeutics and 0 mentions for Elutia. Artiva Biotherapeutics' average media sentiment score of 0.67 beat Elutia's score of 0.00 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Elutia	Neutral
Artiva Biotherapeutics	Positive

Elutia has higher revenue and earnings than Artiva Biotherapeutics. Artiva Biotherapeutics is trading at a lower price-to-earnings ratio than Elutia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elutia	$12.29M	3.45	$53.38M	$0.86	1.15
Artiva Biotherapeutics	$250K	672.38	-$83.86M	-$3.54	N/A

Elutia presently has a consensus target price of $6.00, indicating a potential upside of 505.94%. Artiva Biotherapeutics has a consensus target price of $39.00, indicating a potential upside of 473.53%. Given Elutia's higher possible upside, equities analysts plainly believe Elutia is more favorable than Artiva Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elutia	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Artiva Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Elutia has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Artiva Biotherapeutics has a beta of 2.4, suggesting that its share price is 140% more volatile than the broader market.

Elutia has a net margin of 312.09% compared to Artiva Biotherapeutics' net margin of 0.00%. Elutia's return on equity of 0.00% beat Artiva Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elutia	312.09%	N/A	-53.97%
Artiva Biotherapeutics	N/A	-73.15%	-62.74%

Summary

Elutia beats Artiva Biotherapeutics on 10 of the 17 factors compared between the two stocks.

Get Elutia News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELUT vs. The Competition

Export

Metric	Elutia	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$42.73M	$3.34B	$6.49B	$11.99B
Dividend Yield	N/A	2.30%	2.67%	5.58%
P/E Ratio	1.15	18.61	23.68	23.74
Price / Sales	3.45	299.45	510.62	109.27
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	1.52	8.04	10.28	6.78
Net Income	$53.38M	$23.89M	$3.57B	$337.51M
7 Day Performance	-4.79%	-3.28%	0.28%	-2.34%
1 Month Performance	-1.96%	2.78%	3.27%	1.88%
1 Year Performance	-47.61%	36.03%	22.22%	25.55%

Elutia Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count
ELUT Elutia	2.8273 of 5 stars	$0.99 -0.9%	$6.00 +505.9%	-47.9%	$42.73M	$12.29M	1.15	180
IMUX Immunic	2.4258 of 5 stars	$14.00 +7.9%	$47.57 +239.8%	+53.0%	$190.71M	N/A	N/A	70
ADAG Adagene	1.7852 of 5 stars	$4.00 +7.5%	$8.00 +100.0%	+63.8%	$189.54M	$7.67M	N/A	260
JMAC Maxpro Capital Acquisition	N/A	$14.09 +0.0%	N/A	+115.4%	$189.20M	N/A	N/A	2,021
UNCY Unicycive Therapeutics	3.603 of 5 stars	$7.07 +0.1%	$24.00 +239.5%	-11.7%	$188.77M	$680K	N/A	9

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELUT) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Elutia (ELUT) Competitors

ELUT vs. IMUX, ADAG, JMAC, UNCY, and ARTV

How does Elutia compare to Immunic?

Summary

How does Elutia compare to Adagene?

Summary

How does Elutia compare to Maxpro Capital Acquisition?

Summary

How does Elutia compare to Unicycive Therapeutics?

Summary

How does Elutia compare to Artiva Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELUT vs. The Competition

Elutia Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Elutia (ELUT) Competitors

ELUT vs. IMUX, ADAG, JMAC, UNCY, and ARTV

How does Elutia compare to Immunic?

Which has higher valuation and earnings, IMUX or ELUT?

Do institutionals & insiders have more ownership in IMUX or ELUT?

Does the media prefer IMUX or ELUT?

Do analysts rate IMUX or ELUT?

Which has more risk and volatility, IMUX or ELUT?

Is IMUX or ELUT more profitable?

Summary

How does Elutia compare to Adagene?

Which has preferable earnings & valuation, ADAG or ELUT?

Is ADAG or ELUT more profitable?

Do analysts prefer ADAG or ELUT?

Which has more volatility and risk, ADAG or ELUT?

Does the media favor ADAG or ELUT?

Do insiders and institutionals believe in ADAG or ELUT?

Summary

How does Elutia compare to Maxpro Capital Acquisition?

Does the media prefer JMAC or ELUT?

Do institutionals & insiders hold more shares of JMAC or ELUT?

Which has stronger earnings and valuation, JMAC or ELUT?

Which has more volatility and risk, JMAC or ELUT?

Do analysts rate JMAC or ELUT?

Is JMAC or ELUT more profitable?

Summary

How does Elutia compare to Unicycive Therapeutics?

Is UNCY or ELUT more profitable?

Which has more volatility and risk, UNCY or ELUT?

Do institutionals and insiders hold more shares of UNCY or ELUT?

Which has better valuation & earnings, UNCY or ELUT?

Does the media refer more to UNCY or ELUT?

Do analysts prefer UNCY or ELUT?

Summary

How does Elutia compare to Artiva Biotherapeutics?

Do insiders & institutionals believe in ELUT or ARTV?

Does the media refer more to ELUT or ARTV?

Which has better valuation and earnings, ELUT or ARTV?

Do analysts rate ELUT or ARTV?

Which has more volatility and risk, ELUT or ARTV?

Is ELUT or ARTV more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELUT vs. The Competition

Elutia Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools